MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ -- Milestone
Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical
company focused on the development and commercialization of
innovative cardiovascular medicines, today announced the
appointment of Lisa Giles and
Robert Wills to its Board of
Directors, effective October 1, 2020.
Ms. Giles will serve as a member of the Audit Committee of the
Board and Dr. Wills will serve as a member of the Nominating &
Corporate Governance Committee of the Board.
"On behalf of the entire Board of Directors, it is a pleasure to
welcome Lisa and Rob, two highly accomplished industry veterans, to
our team," said Joseph Oliveto,
President and Chief Executive Officer of Milestone Pharmaceuticals.
"Their collective experience across a range of diverse strategic
roles will be highly instrumental as we continue to advance our
Phase 3 program of etripamil for the treatment of paroxysmal
supraventricular tachycardia, prepare for commercialization, and
build out our pipeline. I look forward to working with them and
leveraging their unique expertise."
Ms. Giles brings to the Milestone Board of Directors over 35
years of experience in the pharmaceutical industry, including
strategic planning, operations, and business development. She is
the founder, managing director and Chief Executive Officer of Giles
& Associates Consultancy, Inc. (GAC). From 2013 until 2020, Ms.
Giles served as Chief Executive Officer of Optivara, Inc., a
cloud-based software and predictive analytics company serving the
life sciences industry. Prior to founding GAC and Optivara, Ms.
Giles was the Vice President of Strategy Development at G.D. Searle
Pharmaceutics, Monsanto; and held various leadership roles with
Abbott Laboratories. She currently serves on the Board of Directors
of GenMark Diagnostics, Inc. (Nasdaq: GNMK) and the Northwestern
Memorial Hospital Foundation, and previously served as a member of
the Board of Directors of Durata Therapeutics, Inc. (Nasdaq: DRTX)
and Intranasal Therapeutics, Inc. She received her B.S. in
Economics from Juniata College, and
completed executive management programs at Stanford University and the University of Chicago.
Dr. Wills joins the Board with over 35 years of experience in
the pharmaceutical industry, including preclinical and clinical
research and development, business development, and strategic
partnering. Prior to his retirement in 2015, Dr. Wills spent over
25 years in a variety of executive roles at Johnson & Johnson,
most recently as Vice President, Alliance Management, where he was
responsible for managing worldwide strategic alliances. Prior to
Johnson & Johnson, he spent ten years in drug development roles
at Hoffmann-La Roche Inc. Dr. Wills currently serves as Chairman of
the Board of Directors of CymaBay Therapeutics, Inc. (Nasdaq: CBAY)
and is on the Board of Directors of Oncternal Therapeutics, Inc.
(Nasdaq: ONCT), Parion Sciences, Inc., and Go Therapeutics, Inc. He
was previously a member of the Board of Directors of GTx, Inc.,
where he served as Executive Chairman and Chair of the Scientific
and Development Committee. Dr. Wills holds a B.S. in Biochemistry
and a M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in
Pharmaceutics from the University of
Texas.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company
focused on the development and commercialization of innovative
cardiovascular medicines. Milestone
Pharmaceuticals operates in Canada and the
United States. For more
information, visit www.milestonepharma.com and follow the
Company on Twitter at @MilestonePharma.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,",
"continue" "estimate," "potential,", "prepare", "intend" and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements are based on Milestone's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include statements regarding, Milestone's future board
members, Milestone's ongoing clinical trials and Milestone's
preparations to commercialize etripamil for PSVT. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include, but are not
limited to, the risks inherent in biopharmaceutical product
development and clinical trials, including the lengthy and
uncertain regulatory approval process, uncertainties related to the
timing of initiation, enrollment, completion and evaluation of
clinical trials, and whether the clinical trials will validate the
safety and efficacy of etripamil for PSVT or other indications,
among others, as well as risks related to pandemics and public
health emergencies, including those related to COVID-19, and
risks related the sufficiency of Milestone's capital resources and
its ability to raise additional capital. These and other risks are
set forth in Milestone's filings with the U.S. Securities and
Exchange Commission, including in its quarterly report on Form 10-Q
for the quarter ended June 30, 2020, under the caption "Risk
Factors." Except as required by law, Milestone assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Contact:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-strengthens-board-of-directors-with-two-new-appointments-301135061.html
SOURCE Milestone Pharmaceuticals, Inc.